BPC-157 + TB-500 (10 mg Blend) Dosage Protocol

Dosing & Reconstitution Overview

This blend pairs BPC-157 (a synthetic pentadecapeptide derived from a gastric protein fragment) with TB-500 (the active fragment of Thymosin Beta-4) in an equal 1:1 ratio — 5 mg of each compound for a 10 mg total fill. The figures below are compiled strictly for laboratory and educational reference; they describe how the blend has been handled and dosed in published models, not a recommendation for use in humans or animals.

For a 10 mg blend vial, adding 3.0 mL of bacteriostatic water yields a total concentration of 3.33 mg/mL (3,333 mcg/mL), which works out to roughly 1.67 mg/mL of each individual peptide. At that fill, one unit on a U-100 insulin syringe equals 0.01 mL and delivers about 33.3 mcg of total blend (≈16.7 mcg of each peptide), so a 600 mcg daily dose is drawn at 18 units (0.18 mL).

Standard (Gradual) Titration Schedule

The gradual schedule opens at a conservative daily amount, lifts briefly into a short loading window, then settles back to a steady maintenance level for the remainder of the cycle. Each dose is split evenly between the two peptides because of the 1:1 fill.

Reconstitution Steps

1. Let the sealed lyophilized blend vial and the bacteriostatic water reach room temperature, then wipe both stoppers with an alcohol swab.
2. Draw 3.0 mL of bacteriostatic water and inject it slowly down the inside wall of the vial — never directly onto the powder pellet.
3. Swirl gently until both peptides fully dissolve. Do not shake; aggressive agitation can shear the peptide chains.
4. The solution should be clear and colourless. Label the vial with the blend concentration (3.33 mg/mL total) and the reconstitution date.
5. Store upright under refrigeration between uses and draw each subsequent dose with a fresh sterile syringe.

Advanced (Aggressive) Titration Schedule

The advanced schedule front-loads the cycle with a higher opening dose to push tissue-repair exposure early, then steps down through a loading week into the same maintenance level as the gradual plan.

Supplies Needed

Daily subcutaneous dosing means syringe and vial counts scale steeply with cycle length. The table below reflects common 8-, 12- and 16-week reference runs.

Protocol Overview

• Research goal: model soft-tissue, tendon and ligament repair via complementary BPC-157 and TB-500 mechanisms.
• Schedule: once-daily subcutaneous administration in the published handling model.
• Dose band: 600–800 mcg total standard, up to 1000 mcg in aggressive arms.
• Cycle length: 8–12 weeks, with optional extension to 16 weeks.
• Fill: 10 mg lyophilized (5 mg + 5 mg), reconstituted to 3.33 mg/mL with 3 mL diluent.
• Storage: −20 °C dry; 2–8 °C once reconstituted.

Dosing Protocol Notes

• Keep administration on a fixed daily cadence — ideally the same time each day — for steady exposure modelling.
• Hold the opening dose for the first two weeks before moving into the loading window.
• At 3.33 mg/mL, remember that one syringe unit ≈ 33.3 mcg of total blend; double-check the unit count against the table for each step.
• The single combined injection delivers both peptides at once, so no separate reconstitution or measurement is needed for BPC-157 versus TB-500.

Storage Instructions

Keep sealed lyophilized blend vials at −20 °C, protected from light, where stability extends for many months. Once reconstituted, refrigerate at 2–8 °C and use within about four to six weeks. Allow refrigerated solution to warm slightly before drawing, avoid repeated freeze-thaw cycles, and store the vial upright to keep the stopper sealed.

Important Handling Notes

• Use a sterile syringe for every draw and never re-enter the vial with a used needle.
• Because dosing is daily, label and date the vial clearly and track remaining volume to plan vial changeovers.
• Keep the solution clear — discard if it turns cloudy or develops particulate.
• Document each draw — date, volume, remaining material — for reproducibility.

How the Blend Works

BPC-157 is a stable pentadecapeptide that, in preclinical models, promotes angiogenesis, modulates nitric-oxide signalling and shows broad cytoprotective activity across gastrointestinal, musculoskeletal and neurological tissue. TB-500, the synthetic counterpart of the Thymosin Beta-4 active region, is an actin-sequestering peptide that drives cell migration, supports wound closure and exerts anti-inflammatory effects. Paired together, the two are studied for their complementary repair pathways: BPC-157 contributes trophic and anti-inflammatory action while TB-500 adds enhanced cell migration and vascularisation, which is the rationale behind combining them in a single 1:1 fill.

Reported Benefits & Side Effects

Benefits observed in research

• Support for accelerated healing of tendons, ligaments, muscle and soft-tissue injuries in preclinical work.
• Gastroprotective and anti-inflammatory properties attributed primarily to BPC-157.
• Wound-healing activity with reduced scarring potential attributed primarily to TB-500.
• Both peptides are generally well tolerated in the published animal literature.

Side effects reported

• Occasional mild injection-site reactions — redness or itching — with subcutaneous administration.
• No significant toxicity has been documented up to high doses in animal studies.
• Effects are generally transient and localised.

Supporting Lifestyle Factors (Research Context)

• Adequate protein intake to supply substrate for the tissue-repair processes being modelled.
• Progressive, controlled loading of the target tissue rather than complete immobilisation, where the study design allows.
• Adequate sleep, hydration and managed inflammation as standard supportive controls.

Injection Technique (Reference Only)

• Clean the vial stopper and the skin with alcohol swabs and let both dry completely.
• Pinch a skinfold and insert the needle at a 45–90° angle into subcutaneous tissue; aspiration is not required for subcutaneous work.
• Inject slowly and steadily, then apply gentle pressure afterward — do not rub the site.
• Rotate sites systematically (abdomen at least two inches from the navel, thighs, upper arms, flank) to avoid lipohypertrophy, and dispose of sharps in an approved container.

References

Related Protocols